DGAP-News: Medios AG successfully holds its annual general meeting in 2022 | News

DGAP-News: Medios AG / Keywords: General Meeting / Various

Medios AG successfully holds its annual general meeting in 2022.

June 21, 2012 / 2:38 pm
The issuer / publisher is responsible for the content of the application.

Press Release

Medios AG successfully holds its annual general meeting in 2022.

  • He decided to modernize the company’s statute
  • Compensation report approved
  • New stock option plan adopted 2022

Berlin, June 21, 2022 Medios AG (Medios), a leading provider of specialist pharmaceutical solutions in Germany, successfully held the 2022 annual general meeting today, which was again held this year virtually due to the ongoing COVID-19 pandemic. The agenda included 14 items on the agenda. About 80.44% of the share capital were represented in total. On the agenda were issues related to corporate governance, such as the introduction of a mandatory “four eyes” rule by removing the exclusive power to represent Management Board members and approving the remuneration report. Moreover, the Ordinary General Meeting approved the creation of a new share option program 2022 and the corresponding Conditional Capital 2022. The Management Board’s proposals regarding the creation of new authorized capital and the permission to issue convertible bonds / bonds with warrants were not accepted. All voting results are available on the Medios AG website at https://medios.ag/investor-relations/hauptversammlung available.

The Management Board explained the business development in the financial year 2021 and in the first quarter of 2022, as well as plans and goals for the current financial year. He also confirmed that forecast for the financial year 2022 and explained the development strategy in detail.

Matthias Gärtner, CEO of Medios AG: We have a clear plan for further profitable development. On the one hand, we promote organic growth, which we want to achieve, among others by significantly increasing the production capacity, expanding the indication areas and focusing on high-margin products. On the other hand, acquisitions aimed at internationalization and entering other segments are also part of our strategy. As the market leader in specialized pharmacy, Medios is in an excellent position for further growth.

this Modernization of the Articles of Association of Medios AG is carried out in the spirit of good corporate governance. It is based on the implementation of the “four eyes” principle so that in the future each member of the Management Board is authorized to represent the company only together with another member of the Management Board or an authorized signatory.

Tested and approved Compensation report is based on a new remuneration system that was already approved by the shareholders at last year’s General Meeting of Shareholders. It not only implements legal requirements, but is also to promote the long-term and sustainable development of the company and take into account the interests of investors. In particular, the remuneration system includes variable, performance-based remuneration components with a long-term stock option program and short-term bonuses based on the company’s success and Sustainable Development Goals (ESG).

FROM Stock options plan 2022 is another building block for the successful implementation of your growth strategy. This allows Medios to associate highly qualified employees with the company in the long run. The anticipated obstacles to exercise should not only motivate employees.

Important dates of Medios AG in the financial year 2022

June 23: Warburg highlights Hamburg
11 August: Half-year financial statements (Q2 and 6M 2022)
September 20: Berenberg and Goldman Sachs Eleventh German Munich Corporate Conference
November 10: Quarterly report (3rd quarter and 9M 2022)
December 7: Berenberg European Conference 2022 Pennyhill Park, Surrey


About Medios AG
Medios AG is a leading provider of specialist pharmaceutical solutions in Germany. As a competent partner and expert, Medios covers all relevant aspects of the supply chain in this area: from the supply of drugs to the production of patient-specific therapies, including blister packaging. The emphasis is on optimal patient care through specialized pharmacies.

Medios AG is the first listed specialist pharmaceutical company in Germany to be listed on the SDAX index. The shares (ISIN: DE000A1MMCC8) are listed on the Regulated Market of the Frankfurt Stock Exchange (Prime Standard).


Claudia Nickolas
Investor and Public Relations Director, ESG Communications
Medios AG
Heidestrasse 9 | 10557 Berlin
T +49 30 232 566 800

Anna Hoffken
Senior Consultant Investor & Public Relations
Kirchhoff Consult AG
Borselstraße 20 | 22765 Hamburg
T +49 40 609 186 34

This press release contains forward-looking statements that involve a number of risks and uncertainties. Future results may differ materially from what is currently expected due to various risk factors and uncertainties, such as business changes, economic and competitive conditions, currency fluctuations, uncertainty about litigation or investigations, and availability of resources.

June 21, 2012 Publication of corporate information / financial message broadcast by DGAP – EQS Group AG website.
The issuer / publisher is responsible for the content of the application.

DGAP’s distribution services include statutory reporting, corporate / financial news, and press releases.
Media archive at http://www.dgap.de

Leave a Comment